Issue 04 | Spring/Summer 2019
Program Newsletter
for Basic and Clinical Research 
We are pleased to distribute this newsletter for the Rutgers Cancer Institute of New Jersey’s Basic Research and Clinical Research Programs. Comprised of content submitted by our Research Program Members, this newsletter will keep you informed of their awards, publications, presentations, and other matters of programmatic importance since the time of the last newsletter (Fall 2018).
Shared Resources
at Rutgers Cancer Institute of New Jersey 
Featured Resource: Biometrics
The Rutgers Cancer Institute of New Jersey Biometrics Shared Resource provides statistical support to the basic, clinical, and population sciences. Investigators are encouraged to consult Biometrics for study design and grant proposals before the start of the study or grant proposal to ensure that the research aims are measurable and achievable with appropriate sample size (e.g. number of laboratory animals or human subjects). Study duration, as well as consistent and clearly defined endpoints, are also often involved in pre-study discussions. Further, Biometrics can assist with data collection formats, which should also be considered at the study design stage. 
       
During the study, Biometrics statisticians may provide appropriate study monitoring and valid interim decision analysis. Interim study decision should usually be factored in as part of study design. There are various types of potential mid-course study adjustment, including but not limited to treatment (dose) adjustment or selection, slow study enrollment, and early termination or enrichment. Unplanned interim decisions may also happen during the study. Statisticians provide insight on ramifications of unplanned interim decisions on scientific validity. When data are available, Biometrics statisticians provide data analysis with the most efficient and modern statistical methods to meet the needs of journal publication or further grant application (for other studies).  
To learn more about the services available from the Biometrics Shared Resource, please visit  the website page or contact Director  Weichung Joe Shih at w.joe.shih@rutgers.edu or 732-235-7592.

Please remember to acknowledge the valuable services provided by the Biometrics Shared Resource in your research papers, publications, and grant applications. The following acknowledgment statement is recommended:

"Services, results and/or products in support of the research project were generated by the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource, supported, in part, with funding from NCI-CCSG P30CA072720."

Please consider including the names of individuals from the shared resource if they provided any intellectual input or additional effort.
IMPORTANT ANNOUNCEMENT

NEW CANCER CENTER SUPPORT GRANT (CCSG)
SUBPROJECT NUMBERS

NCI has now assigned a unique subproject number for each CCSG component. When acknowledging the CCSG in publications that resulted from Pilot Award/New Investigator funds and/or use of any supported  Shared Resource  – please use all of the appropriate CCSG grant numbers from the following:  
2 Important Reminders

1. Please acknowledge the CCSG   in publications that resulted from any CCSG support: such as Pilot Award/New Investigator funds, use of Office of Human Research Services (OHRS), and/or use of any supported  Shared Resource .

Example:  "Services, results and/or products in support of the research project were generated by the Rutgers Cancer Institute of New Jersey Biomedical Informatics Shared Resource, supported, in part, with funding from NCI-CCSG P30CA072720."  (Note: please also consider including names of individuals from shared resources if they provided any intellectual input or additional effort.)

2. P ublications that acknowledge the CCSG must comply with the   NIH Public Access Policy .

(NOTE:  PMID  vs. PMCID  – PubMed (PMID) is an index of abstracts; PubMed Central (PMCID) is an index of full-text papers and a PMCID  is  required  when you publish research that was supported by any NIH funding.)  
Recent Conferences & Retreats
Tri-State Metabolism Meeting




On December 14, 2018, Princeton University hosted the Tristate Cancer Metabolism Meeting. This day-long meeting occurs once or twice per year brings together cancer metabolism researchers from Rutgers University, Princeton University, Memorial-Sloan Kettering Cancer Center, Weill Cornell Medical College, University of Pennsylvania, and New York University.
Attendance to the December 2018 Tristate
Cancer Metabolism Meeting
Dr. Ping Xie presenting
Vrushank Bhatt presenting
Presenters at this meeting included Jon Ghergurovich ( Joshua D. Rabinowitz, MD, PhD laboratory),  Ping Xie, PhD , and Vrushank Bhatt ( Yanxiang (Jessie) Guo, PhD laboratory).  
Crash Course:
Small Molecule Screening/Drug Discovery Ecosystem
On Monday, March 25, 2019,  X.F. Steven Zheng, PhD and  Stephen K. Burley, MD, DPhil , Co-Leaders of the  Cancer Pharmacology Research Program , collaborated with  Tom W. Muir, PhD to host  Crash Course: Small Molecule Screening/Drug Discovery Ecosystem . This event was jointly organized by the Princeton University Department of Chemistry, Rutgers University Institute for Quantitative Biomedicine, and Rutgers Cancer Institute of New Jersey. Featuring presentations by  S. David Kimball, PhD ,  X.F. Steven Zheng, PhD , Stephen K. Burley, MD, DPhil ,  Hahn Kim, PhD , Nilgun E. Tumer, PhD , David J. Augeri, PhD , and Jon Ghergurovich (PhD Candidate in the laboratory of  Joshua D. Rabinowitz, MD, PhD ), the crash course provided an afternoon of learning about the capabilities of the developing Small Molecule Screening Shared Resource and the unique opportunities for drug discovery and other innovative health research offered through the cancer research consortium relationship between Rutgers University and Princeton University. Event participation totaled more than 60 in-person attendees, with many others accessing the presentations remotely via live streaming. PDF versions of the presentation slide decks can be downloaded from the Institute for Quantitative Biomedicine website ( iqb.rutgers.edu ).
 
Investigators interested in learning more about the capabilities of the Small Molecule Screening Shared Resource should contact Dr. Hahn Kim at  hkim@princeton.edu or 609-258-0131. Investigators who would like to propose a research project for this Shared Resource should contact Dr. Burley at  sburley@proteomics.rutgers.edu . Investigators interested in accessing the Rutgers Fragment Screening Resource should contact Dr. Nilgun Tumer at  tumer@sebs.rutgers.edu . Investigators interested in learning more about the capabilities of the Rutgers Molecular Design and Synthesis Facility should contact Dr. David Augeri at  dja143@ored.rutgers.edu . Investigators interested in using the Protein Data Bank can access more than 150,000 experimentally-determined three-dimensional structures of proteins and nucleic acids via rcsb.org without charge or limitations on usage.
Speakers and attendees to the 2019  Crash Course: Small Molecule Screening/Drug Discovery Ecosystem  event
The Governor’s Conference on Effective Partnering in Cancer Research:
Novel Technologies in Cancer Research
On April 11, 2019, Rutgers Cancer Institute of New Jersey partnered with the Institute for Advanced Study to host the annual Governor’s Conference on Effective Partnering in Cancer Research. Titled “Novel Technologies in Cancer Research”, this event featured local and international researchers presenting on cutting-edge topics in innovative cancer research technology. It also provided a conducive atmosphere for networking between researchers and industry partners from throughout New Jersey and the surrounding region. Presentations were given by Serena Nik-Zainal (University of Cambridge), Harlan Robins (Fred Hutchinson Cancer Research Center), Marta Łuksza (Icahn School of Medicine at Mount Sinai), Michael B. Elowitz (California Institute of Technology), and Rutgers Cancer Institute member  Shawn M. Davidson, PhD (Princeton University). 

Dr. Shawn M. Davidson presenting
2019 Annual Retreat on Cancer Research in New Jersey
Rutgers Cancer Institute of New Jersey, in collaboration with the New Jersey Commission on Cancer Research, hosted the 2019 Annual Retreat on Cancer Research in New Jersey, on May 23, 2019 at the Rutgers University College Avenue Student Center. The day began with a poster session and a Public Forum covering ScreenNJ and its work on Cancer Prevention, Education, and Detection. Rutgers Cancer Institute Director Steven K. Libutti, MD, FACS then gave a Welcome and Introduction.
Dr. Steven K. Libutti gives the
Welcome and Introduction
Dr. Rosenberg gives the Keynote Address






Steven A. Rosenberg, MD, PhD, Chief of the Surgery Branch of the National Cancer Institute, was the Keynote Speaker, and presented “Cellular Immunotherapy for the Common Epithelial Cancers”.
The annual retreat concluded with afternoon focus sessions from the five Research Programs . 
Presentations at the Focus Sessions
Cancer Metabolism & Growth
Meet Our New Members!
Awards and Honors

Peter Lobel, PhD was awarded an NIH high end shared instrumentation grant S10OD025140 entitled “An Orbitrap Tribrid mass spectrometer and nanoflow LC system to upgrade the proteomics facility at Rutgers-New Brunswick and Robert Wood Johnson Medical School”. Term: 06/18/2019 – 06/17/2020. Amount: $921,333.  

M. Maral Mouradian, MD is the recipient of the Rutgers Robert Wood Johnson Medical Honorary Alumni Award, which will be presented to her at the School’s Scholarship Gala on April 6, 2019 at the Heldrich Hotel in New Brunswick, NJ.

M. Maral Mouradian, MD was awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research Grant ID: 12350.01 entitled “Transglutaminase 2 Inhibition as a Disease Modifying Therapeutic Strategy in Parkinson’s Disease.” Term 3/1/19 – 2/28/21. Amount: $180,000
Presentations
Eileen White, PhD presented “Regulation of mammalian and cancer metabolism by autophagy" at the CanCell Mini Symposium held June 11 – 12, 2019 at University of Oslo, Oslo, Norway.

Vrushank Bhatt, a graduate student in the laboratory of  Yanxiang Jessie Guo, PhD presented “Autophagy Supports Tumor Growth and Metastases in Lkb1-Deficient Kras-Driven Lung Tumorigenesis” at the 2019 Annual Retreat on Cancer Research in New Jersey, held May 23, 2019 at Rutgers University in New Brunswick, NJ.

Eileen White, PhD presented “Autophagy maintains tumor growth through 
different mechanisms depending on neoantigen load” at Mechanisms of Metabolic Signaling held May 14 – 18, 2019 in Cold Spring Harbor, NY.

Eileen White, PhD presented “Role of autophagy in cancer” at the Cancer Metabolism Seminar Series held May 9, 2019 at University of Utah, Salt Lake City, UT.

Eileen White, PhD presented “Autophagy in host and tumor metabolism” at the 2019 AACR Annual Meeting held March 29 – April 3, 2019 in Atlanta, GA, USA.

Eileen White, PhD presented “Mitochondria and Cancer” at Mitochondria: From Basic Biology to Mechanisms of Disease Conference held February 27 – March 2, 2019 in Nassau, Bahamas.

Eileen White, PhD presented “Autophagy Maintains Host and Tumor Metabolism and an Anti-Cancer Immune Response” at Tumor Metabolism (B5) held February 24- 28, 2019 in Keystone, CO, USA.

Eileen White, PhD presented “Autophagy Maintains Host and Tumor Metabolism and an Anti-Cancer Immune Response” at Autophagy: From Model Systems to Therapeutic Opportunities held February 17—21, 2019 in Santa Fe, NM.

M. Maral Mouradian, MD presented two talks about research advances in Parkinson’s disease in her laboratory to groups of Rutgers alumni and their guests in Palm Beach, FL, at events organized by the Rutgers Foundation on January 15-16, 2019.







Jessie Yanxiang Guo, PhD gave an invited lecture entitled “Role of Autophagy in KRAS-driven NSCLC” on January 11, 2019 at Shanghai Tech University, Shanghai, China.
Dr. Jessie Yanxiang Guo presenting
Eileen White, PhD presented “Autophagy and cancer metabolism” at the AACR Special Conference: Targeting PI3K/mTOR Signaling held November 30 – December 3, 2018 in Boston, MA.

Kenneth D. Irvine, PhD presented   “Biomechanical regulation of Hippo Signaling” at the 9th Xiamen Winter Symposium: The Hippo Signaling Pathway in Development and Disease, held November 2-6, 2018 in Xiamen, China. 

Eileen White, PhD presented “Novel Approaches to Cancer Therapy Targeting Cancer Metabolism” at the Stanford Biology Seminar Series held November 5, 2018 at Stanford University, Palo Alto, CA.

Kenneth D. Irvine, PhD presented   “Biomechanical regulation of Organ Growth” at the Chilean Society for Cell Biology XXXII Annual Meeting, held October 22-26, 2018 in Puerto Varas, Chile.
Selected Publications

Tsang CK, Chen M, Cheng X, Qi Y, Chen Y, Das I, Li X, Vallat B, Fu LW, Qian CN, Wang HY, White E , Burley SK, Zheng XFS. SOD1 Phosphorylation by mTORC1 Couples Nutrient Sensing and Redox Regulation. Mol Cell. 2018;70(3):502-15.e8. Epub 2018/05/05. doi: 10.1016/j.molcel.2018.03.029. PubMed PMID: 29727620; PMCID: PMC6108545.

Bhatt V, Khayati K, Hu ZS, Lee A, Kamran W, Su X, Guo JY . Autophagy modulates lipid metabolism to maintain metabolic flexibility for Lkb1-deficient Kras-driven lung tumorigenesis. Genes Dev. 2019;33(3-4):150-65. Epub 2019/01/30. doi: 10.1101/gad.320481.118. PubMed PMID: 30692209; PMCID: PMC6362813.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY , Lattime E, Rabinowitz JD, White E . Autophagy maintains tumour growth through circulating arginine. Nature. 2018;563(7732):569-73. Epub 2018/11/16. doi: 10.1038/s41586-018-0697-7. PubMed PMID: 30429607; PMCID: PMC6287937.

Oh SE, Park HJ, He L, Skibiel C, Junn E, Mouradian MM . The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. Redox biology. 2018;19:62-73. Epub 2018/08/15. doi: 10.1016/j.redox.2018.07.021. PubMed PMID: 30107296; PMCID: PMC6092527.
Cancer Pharmacology
Meet Our New Members!
Awards and Honors

Daniel Herranz Benito, PhD was recently accepted into the  Interstellar Initiative   mentoring program by the New York Academy of Sciences and the Japan Agency for Medical Research and Development (AMED). 

Daniel Herranz Benito, PhD was awarded a National Cancer Institute (NCI) R01CA236936 Grant, entitled “The role of glutaminolysis as a therapeutic target in T-ALL”. Term: 07/01/2019 – 06/30/2024. Amount: $1,791,572.

Daniel Herranz Benito, PhD was awarded a Gabrielle’s Angel Foundation for Cancer Research Award, entitled “The role of SIRT1 in the pathogenesis and treatment of T-Cell Acute Lymphoblastic Leukemia”. Term: 04/04/2019 – 03/31/2022. Amount: $225,000 .

Joachim B. Kohn, PhD is a recipient of a 2019 Society for Biomaterials Award.

Fred Russell Kramer, PhD is the Principal Investigator on a Rutgers TechAdvance TA2018-0287 award, entitled “Sensitive, Multiplex PCR Assays that Assess the Abundance of Rare Somatic Mutations Associated with Cancer”.  Term 1/1/19 – 12/31/19. Amount: $100,000.

Daniel Herranz Benito, PhD was awarded a Children’s Leukemia Research Association Grant, entitled “SIRT1 metabolic and transcriptional effects in T-ALL”. Term: 01/01/2019 – 12/31/2019. Amount: $30,000.
Presentations
Daniel Herranz Benito, PhD presented “Novel metabolic and epigenetic targets for the treatment of T-Cell Acute Lymphoblastic Leukemia” at the National Cancer Institute (NCI), Bethesda, MD on 06/17/2019.

Fred Russell Kramer, PhD presented “Extraordinarily Sensitive, Multiplex PCR Assays that Assess the Abundance of Rare Somatic Mutations Associated with Cancer Diagnosis, Prognosis, and Therapy” on November 30, 2018 at University of Delaware Department of Medical and Molecular Sciences in Newark, DE. 

Fred Russell Kramer, PhD presented “Extraordinarily Sensitive, Multiplex PCR Assays that Assess the Abundance of Rare Somatic Mutations Associated with Cancer Diagnosis, Prognosis, and Therapy” for the monthly Clinical Investigations and Precision Therapeutics Research Program meeting held November 13, 2018 at Rutgers Cancer Institute of New Jersey in New Brunswick, NJ.

Fred Russell Kramer, PhD presented “Multiplex Real-Time PCR Assays that Assess the Abundance of Rare Somatic Mutations Associated with Cancer” at SelectBIO Exosomes and Liquid Biopsies Europe held October 24-26, 2018 in Rotterdam, The Netherlands.

Fred Russell Kramer, PhD presented “Extraordinarily Sensitive, Multiplex PCR Assays that Assess the Abundance of Rare Mutations Associated with Cancer, Utilizing Liquid Biopsy Samples” at the Global Engage 4BIO Summit held September 13-14, 2018 in San Francisco, CA. 
Selected Publications

Ji S, Dube K, Chesterman JP, Fung SL, Liaw CY, Kohn J , Guvendiren M. Polyester-based ink platform with tunable bioactivity for 3D printing of tissue engineering scaffolds. Biomaterials science. 2019;7(2):560-70. Epub 2018/12/12. doi: 10.1039/c8bm01269e. PubMed PMID: 30534726; PMCID: PMC6351207.

Mao Y, Block T, Singh-Varma A, Sheldrake A, Leeth R, Griffey S, Kohn J . Extracellular matrix derived from chondrocytes promotes rapid expansion of human primary chondrocytes in vitro with reduced dedifferentiation. Acta biomaterialia. 2019;85:75-83. Epub 2018/12/12. doi: 10.1016/j.actbio.2018.12.006. PubMed PMID: 30528605.

Merolli A, Louro P, Kohn J . Reciprocal nerve staining (RNS) for the concurrent detection of choline acetyltransferase and myelin basic protein on paraffin-embedded sections. Journal of neuroscience methods. 2019;311:235-8. Epub 2018/11/06. doi: 10.1016/j.jneumeth.2018.10.040. PubMed PMID: 30391262; PMCID: PMC6319371.

Vargas DY, Marras SAE, Tyagi S, Kramer FR . Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic Mutations. The Journal of molecular diagnostics : JMD. 2018;20(4):415-27. Epub 2018/04/27. doi: 10.1016/j.jmoldx.2018.03.004. PubMed PMID: 29698835.
Clinical Investigations &
Precision Therapeutics
Meet Our New Members!
Presentations

‌
Rajat Bannerji, MD, PhD presented “Emerging Clinical Activity of REGN 1979, an Anti-CD20 X anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma” as a podium presentation at the 24 th  Annual Congress of the European Hematology Association (EHA) held June 13-16, 2019 in Amsterdam, the Netherlands.

Dr. Rajat Bannerji presenting
Dr. Janice M. Mehnert presenting

Janice M. Mehnert, MD presented “GITR as an Emerging Novel Checkpoint in Immunotherapy” and “Immunotherapy Versus BRAF/MEK Inhibitors in the Adjvuant Setting: Is There a Clear Winner?” at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31-June 4, 2019 in Chicago, IL. 
Selected Publications

Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S , Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM. RET rearrangements are actionable alterations in breast cancer. Nature communications. 2018;9(1):4821. Epub 2018/11/18. doi: 10.1038/s41467-018-07341-4. PubMed PMID: 30446652; PMCID: PMC6240119.
Genomic Instability & Cancer Genetics
Meet Our New Members!
Awards and Honors

Nahed Jalloul, postdoctoral appointee in the laboratory of Hossein Khiabanian, PhD , received a Gallo award and was a presenter at the 2019 Annual Retreat on Cancer Research in New Jersey, held May 23, 2019.

Hossein Khiabanian, PhD was awarded a National Cancer Institute (NCI) R01CA233662 Grant, entitled “Evolution and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in Breast Tumor Microenvironment”. Term: 5/1/2019 – 4/30/2024. Amount: $3.2 million.

Subhajyoti De, PhD was awarded a National Institutes of Health (NIH) R01GM129066 Grant entitled “Computational approaches for identifying epigenomic contexts of somatic mutations”. Term: 04/01/2019 – 03/31/2024. Amount: 1,680,585. 

Nahed Jalloul, postdoctoral appointee in the laboratory of Hossein Khiabanian, PhD received a NJCCR postdoctoral fellowship entitled "Bioinformatic Analysis of Clinical Sequencing Data for Interpreting Tumor Mutations". Term: 01/01/2019 – 12/31/2020. Amount: $100,000.

Presentations

Nahed Jalloul, postdoctoral appointee in the laboratory of Hossein Khiabanian, PhD presented "Bioinformatic Analysis of Clinical Tumor Sequencing Data" at the 2019 Annual Retreat on Cancer Research in New Jersey, held May 23, 2019 at Rutgers University in New Brunswick, NJ.

David E. Axelrod, PhD presented an invited research seminar “Therapy and prevention of early colon cancer by computer optimized dose schedules” at the Integrated Mathematical Oncology Department, Moffitt Cancer Center, Tampa, FL on April 25, 2019. 

Jui Wan Loh, a PhD candidate in the laboratory of Hossein Khiabanian, PhD presented “Inference of specimen purity from variant allele frequencies in tumor-only clinical sequencing data” at the 2018 Biological Data Science Meeting held November 7-10, 2018 at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Selected Publications

Singh A, Bhanot G,  Khiabanian H . TuBA: Tunable biclustering algorithm reveals clinically relevant tumor transcriptional profiles in breast cancer. Gigascience. 2019;8(6). Epub 2019/06/20. doi: 10.1093/gigascience/giz064. PubMed PMID: 31216036; PMCID: PMC6582332. This new computational method was also covered on the   Rutgers Cancer Institute website and in an  article by NJBiz.com .

Wong C, Tang LH, Davidson C, Vosburgh E, Chen W, Foran DJ, Notterman DA, Levine AJ,  Xu EY . Two well-differentiated pancreatic neuroendocrine tumor mouse models. Cell Death Differ. 2019. Epub 2019/06/05. doi: 10.1038/s41418-019-0355-0. PubMed PMID: 31160716.

Loh JW,  Khiabanian H . Leukemia’s Clonal Evolution in Development, Progression, and Relapse. Current Stem Cell Reports. 2019;5(2):73-81.

Blasco MT, Navas C, Martin-Serrano G, Grana-Castro O, Lechuga CG, Martin-Diaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Paton J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B, Jr., Dusetti N, Iovanna J, Sanchez-Bueno F, Hidalgo M, Khiabanian H , Rabadan R, Al-Shahrour F, Guerra C, Barbacid M. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell. 2019;35(4):573-87.e6. Epub 2019/04/13. doi: 10.1016/j.ccell.2019.03.002. PubMed PMID: 30975481.

Cockrell C, Axelrod DE . Optimization of Dose Schedules for Chemotherapy of Early Colon Cancer Determined by High-Performance Computer Simulations. Cancer Inform. 2019;18:1176935118822804. Epub 2019/01/25. doi: 10.1177/1176935118822804. PubMed PMID: 30675100; PMCID: PMC6330731.

Riedlinger G, Hadigol M, Khiabanian H *, Ganesan S. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms. JAMA oncology. 2019. Epub 2019/01/04. doi: 10.1001/jamaoncol.2018.6286. PubMed PMID: 30605212. This publication was featured in GenomeWeb .

Nobel YR, Snider EJ, Compres G, Freedberg DE, Khiabanian H , Lightdale CJ, Toussaint NC, Abrams JA. Increasing Dietary Fiber Intake Is Associated with a Distinct Esophageal Microbiome. Clinical and translational gastroenterology. 2018;9(10):199. Epub 2018/10/26. doi: 10.1038/s41424-018-0067-7. PubMed PMID: 30356041; PMCID: PMC6200756.

  *Corresponding Author
Basic Research & Clinical Research Programs 
Rutgers Cancer Institute of New Jersey